UCB Stock Forecast, Price & News

UCB (OTCMKTS:UCBJF) Frequently Asked Questions

Is UCB a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UCB stock.
View analyst ratings for UCB or view top-rated stocks.

How has UCB's stock price been impacted by Coronavirus (COVID-19)?

UCB's stock was trading at $97.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UCBJF shares have increased by 13.1% and is now trading at $109.96.
View which stocks have been most impacted by COVID-19.

Are investors shorting UCB?

UCB saw a increase in short interest in December. As of December 31st, there was short interest totaling 768,200 shares, an increase of 51.4% from the December 15th total of 507,300 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 7,682.0 days.
View UCB's Short Interest.

What price target have analysts set for UCBJF?

8 brokers have issued 12 month price objectives for UCB's stock. Their forecasts range from $91.00 to $150.00. On average, they expect UCB's share price to reach $116.77 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for UCB or view top-rated stocks among Wall Street analysts.

Who are UCB's key executives?

UCB's management team includes the following people:

• Jean-Christophe Tellier, Chief Executive Officer & Executive Director
• Sandrine Dufour, Chief Financial Officer & Executive Vice President
• Iris Löw-Friedrich, Chief Medical Officer & EVP-Development
• Dhavalkumar Patel, Chief Scientific Officer & Executive VP
• Herman de Prins, Chief Information Officer

Who are some of UCB's key competitors?

Some companies that are related to UCB include Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Bayer Aktiengesellschaft (BAYRY), Takeda Pharmaceutical (TAK), Astellas Pharma (ALPMY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Royalty Pharma (RPRX), BeiGene (BGNE), Genmab A/S (GMAB), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), Shiseido (SSDOY), Horizon Therapeutics Public (HZNP), Viatris (VTRS) and Catalent (CTLT).
View all of UCBJF's competitors.

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $109.96.

How much money does UCB make?

UCB has a market capitalization of $20.78 billion and generates $6.11 billion in revenue each year.

How many employees does UCB have?

UCB employs 8,371 workers across the globe.

When was UCB founded?

UCB was founded in 1928.

What is UCB's official website?

The official website for UCB is www.ucb.com.

Where are UCB's headquarters?

UCB is headquartered at Allee de la Recherche 60, Brussels C9, 1070.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at (322) 559-9999, via email at [email protected], or via fax at 32-2559-9900.